PTX-35

Reprogramming Immunity and Providing a Long-term, Durable Clinical Effect

Pelican’s lead product candidate targeting the T-cell co-stimulator, TNF receptor superfamily member 25 (“TNFRSF25”). Currently, in preclinical IND enabling activities, PTX-35 is designed to harness the body's natural antigen-specific immune activation and tolerance mechanisms to reprogram the immunity and provide a long-term, durable clinical effect. When combined with immunotherapies, including the ImPACT® and ComPACT™ platform technologies, PTX-35 has been shown to enhance antigen-specific T-cell activation to eliminate tumor cells in patients.

In June 2016, Pelican was awarded a $15.2 million Cancer Prevention Institute of Texas (CPRIT) grant (the “CPRIT Grant”) to support further development of PTX-35 and fund a 70-patient Phase 1 clinical trial to explore the use of PTX-35 in several types of cancers.

Combination Therapies Indication Preclinical Phase 1 Phase 2 Phase 3 Market Comments

PTX-35

(viagenpumatucel-L)

TBA
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
Humanized monoclonal antibody, functional agonist of human TNFRSF25